<DOC>
	<DOCNO>NCT00414180</DOCNO>
	<brief_summary>To determine efficacy safety bupropion SR quit tobacco smokeless tobacco user .</brief_summary>
	<brief_title>Bupropion SR Treating Smokeless Tobacco Use</brief_title>
	<detailed_description>CONTEXT : No pharmacotherapies show increase long-term ( &amp; # 8805 ; 6 month ) tobacco abstinence rate among smokeless tobacco ( ST ) user , although bupropion SR demonstrate potential efficacy pilot study . OBJECTIVE : To determine efficacy safety bupropion SR tobacco abstinence among ST user compare placebo . DESIGN , SETTING , AND PARTICIPANTS : A randomized , double-blind , placebo-controlled trial conduct August 2003 May 2005 two research center 12-week treatment period follow-up smoking status week 52 . INTERVENTION : Bupropion SR titrate 150 mg twice daily placebo 12 week plus weekly behavioral intervention . Main Outcome Measures : The primary endpoint 7-day point-prevalence tobacco abstinence rate week 12 . Secondary outcome include prolonged continuous tobacco abstinence rate week 12 , 24 , 52 .</detailed_description>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Lobeline</mesh_term>
	<criteria>18 year age old use ST daily least one year good general health willing complete study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>